Platinum-Based Combination Chemotherapy for the Treatment of Advanced-Stage Squamous Cell Carcinoma of the Vulva

Belotte, J; Awonuga, Awoniyi O.; Bolinjkar, Rashmi; Alexis, Mitchell; Tabassum, Farah; Deppe, Gunter

doi:10.1097/aog.0b013e318254fe64

Cited by 7 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 17 out of 20 (85%) patients, complete or partial response was found after 3-6 cycles of paclitaxel-carboplatin. In 12 out of 20 (60%) patients, surgical treatment after chemotherapy was possible [10][11][12][13][14][15]. One advantage of the use of paclitaxel-carboplatin is the vast experience clinicians have in ovarian, cervical, and endometrial cancer.…”

Section: Discussionmentioning

confidence: 99%

Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer

Amant

Nooij

Annibali

et al. 2018

Gynecol Obstet Invest

View full text Add to dashboard Cite

In this brief report, we present our experience with 3-weekly paclitaxel-carboplatin chemotherapy for patients with vulvar cancer. Two patients with locally advanced disease had an impressive response allowing standard vulvar cancer surgery. One patient with metastatic disease had local stable disease though it was progressive in the lymph nodes. The available literature is sparse and retrospective. Based on promising results, however, a prospective multicenter study is mandatory in order to obtain full data in a larger series of patients in order to learn the benefits of neoadjuvant paclitaxel-carboplatin and compare the results with chemoradiation.

show abstract

Section: Discussionmentioning

confidence: 99%

Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer

Amant

Nooij

Annibali

et al. 2018

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…There are no published prospective trials; however, one retrospective review and several case studies of uterine, vulvar, and vaginal cancers in people living with HIV suggested that patients may present at younger age, respond less to treatment, and have a more aggressive course. One case report of vulvar carcinoma found complete response in a patient treated with definitive chemoradiotherapy 39–42…”

Section: Uterine Ovarian and Vulvovaginal Malignancies In People Livi...mentioning

confidence: 99%

“…One case report of vulvar carcinoma found complete response in a patient treated with definitive chemoradiotherapy. [39][40][41][42] A retrospective review by Levinson et al evaluated 57 patients with gynecological malignancies and HIV (15 vulvar, 26 cervical, nine ovarian, and seven endometrial) treated in the USA. Seventythree percent of patients with stage I disease received NCCNconcordant care compared with only 22% of patients with stage II-IV disease.…”

Section: Cancer Outcomesmentioning

confidence: 99%

Gynecological radiotherapy in people living with human immunodeficiency virus: a semi-systematic literature review

Fenlon

Rositch

Dickey

et al. 2022

Int J Gynecol Cancer

View full text Add to dashboard Cite

Appropriate diagnosis and treatment of gynecological cancers in people living with human immunodeficiency virus (HIV) remains a clinical challenge given rapid changes in both HIV and cancer management and a lack of prospective clinical trial data inclusive of the HIV population. A semi-systematic literature review was performed to identify published studies addressing risk factors, screening, treatment efficacy, treatment toxicity, and prognosis for people living with HIV diagnosed with gynecological malignancies, with a focus on radiotherapy and cervical cancer, given the relative paucity of literature on uterine, ovarian, and vulvovaginal cancers in people living with HIV. People living with HIV are more likely to be co-infected with human papilloma virus and more likely to develop human papilloma virus-associated malignancies. People living with HIV are less likely to receive cancer treatment compared with HIV-uninfected cancer patients, even after adjusting for differences in clinical features and sociodemographic variables. The literature on cervical cancer outcomes is mixed, with some studies demonstrating that people living with HIV have inferior treatment tolerability, response rates, and survival following chemoradiotherapy, and others showing no difference in these outcomes, particularly in patients receiving antiretroviral therapy. Importantly, even in the series showing inferior outcomes in people living with HIV, there were long-term survivors after administration of curative therapy. Consistent with published cancer management guidelines, people living with HIV diagnosed with gynecological cancers should be treated with standard cancer therapy. Co-management with the patient’s HIV specialist is critical to avoid overlapping toxicities and provide optimal supportive care. The morbidity and mortality caused by gynecologic cancers in this population can be mitigated by early diagnosis, appropriate treatment delivery including inclusion of people with HIV in cancer clinical trials, and diligent HIV management.

show abstract

“…The benefits of neoadjuvant chemotherapy alone include possible elimination of microscopic metastases, decrease in tumor bulk and therefore decrease in radicality of surgery and therefore a decreased risk of perioperative morbidity. Single agent therapy with paclitaxel, 58,59 cisplatin, 60 bleomycin 61 or combinations consisting of cisplatin/ paclitaxel, 61,62 cisplatin, bleomycin and methotrexate, 63 cisplatin/5-FU, 60 cisplatin/topotecan 64 or cisplatin/ vinorelbine 65 have shown activity in squamous cell carcinoma of the vulva with objective response rates between 20% and 100% based on the studies examined. 11 Interestingly, Geisler et al demonstrated 100% response rate in 10 patients with locally advanced vulvar cancer using cisplatin and 5-FU with sparing of both the anal sphincter and urethra in all patients.…”

Section: Role Of Chemotherapymentioning

confidence: 99%

Management of squamous cell vulvar cancer: A review

Deppe

Mert

Winer

2014

J of Obstet and Gynaecol

Self Cite

View full text Add to dashboard Cite

Squamous cell vulvar cancer is a rare gynecologic malignancy. Standard treatment for early stage disease consists of wide radical excision of the primary tumor with inguinal-femoral lymphadenectomy or sentinel lymph node mapping/biopsy. Because of the general paucity of patients with advanced vulvar cancer, there is no standard therapy for advanced disease and therefore treatment should be individualized. Intergroup trials are needed to clarify the value of chemoradiation, neoadjuvant chemotherapy and targeted therapy in patients with advanced squamous cell cancer of the vulva to identify modalities with the best therapeutic index and lowest morbidity.

show abstract

Platinum-Based Combination Chemotherapy for the Treatment of Advanced-Stage Squamous Cell Carcinoma of the Vulva

Abstract: Platinum-based combination chemotherapy may be used successfully for patients with advanced-stage squamous carcinoma of the vulva.

Cited by 7 publications

References 9 publications

Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer

Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer

Gynecological radiotherapy in people living with human immunodeficiency virus: a semi-systematic literature review

Management of squamous cell vulvar cancer: A review

Contact Info

Product

Resources

About